personalized breast cancer care
DESCRIPTION
Personalized Breast Cancer Care. Sunil Patel, MD Medical Oncology and Hematology Collom and Carney Clinic. No financial disclosure. Personalized Breast Cancer Care Topics. Role of genetic/familial high risk assessment - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/1.jpg)
Personalized Breast Cancer Care
Sunil Patel, MDMedical Oncology and Hematology
Collom and Carney Clinic.
![Page 2: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/2.jpg)
No financial disclosure
![Page 3: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/3.jpg)
Personalized Breast Cancer CareTopics
• Role of genetic/familial high risk assessment• Role of specific markers on breast tissue in
decision making of treatment.• For some patients, more(=chemo) is not
better. - Role of genetic profiling of the tumor in decision making.
![Page 4: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/4.jpg)
Breast Cancer Progress Report
• Breast Cancer mortality rates have decreased by 2.3% annually since 1990
Source: Breast Cancer Facts and Figures 2005-2006 National Center for Health Statistics data as analyzed by NCI
• The decline in mortality is primarily due to early detection and new treatment methods
![Page 5: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/5.jpg)
The Stages of Breast Cancer
Breast Cancer is diagnosed according to stages (stages 0 through IV) under the TNM classification. Factors used in staging of Breast Cancer:
• Tumor SizeSize of primary tumor
• Nodal statusIndicates presence or absence of cancer cells in lymph nodes
• MetastasisIndicates if cancer cells have spread from the affected breast to other areas of the body (i.e. skin, liver, lungs, bone)
Source: National Cancer Institute
![Page 6: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/6.jpg)
Genetics Help us Identify Patients at High Risk of Developing Breast CancerGenetics – Genetics is the study of heredity• While genetics influence genomics, genetics is responsible for
only 5-10% of breast cancer
• Genetics focuses primarily on the likelihood of developing cancer
• Genetic tests find mutations, not disease
Source: Understanding Cancer Series: Gene Testing,National Cancer Institute
![Page 7: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/7.jpg)
Genomics Help us Look at the Patients Individual Tumor Biology
Genomics Genomics is the study of how genes interact and are
expressed as a whole• Genomics and gene expression profiling tools focus on the
cancer itself and can help determineHow aggressive is the cancer (prognosis)What is the likely benefit from treatment (prediction)
![Page 8: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/8.jpg)
Examples of Genetic and Genomic Tests
Genetic Test
• BRCA1 and BRCA2 • The genetic make up of patients is tested for BRCA1 and BRCA2 mutations. Patients with those mutations have higher chances of developing breast cancer.
Genomic Test• Oncotype DX® Breast Cancer Assay
• The expression level of 21 genes is measured in tumor tissue from patients that have already been diagnosed with breast cancer. This assay evaluates if a patient is going to recur (prognostic) and predicts benefit from chemotherapy and hormonal therapy (predictive)•Mammaprint assay
![Page 9: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/9.jpg)
Genetic Risk Factor Assessment
• NX 42 year old white female with no family history of breast cancer, now has 4 cm right breast cancer.
• Biopsy confirmed IDC,ER+, HER2/neu +• What’s next? – Surgery- ipsilateral or bilateral
mastectomy, chemo, hormonal therapy? Or more?
![Page 10: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/10.jpg)
Breast & Ovarian Cancer Risk Assessment – for patients
- Age 50 y or younger- Triple negative breast cancer ( ER-PR-Her2/Neu-)- Two breast cancer primaries- Breast cancer at any age - 1 or more close relative with breast or ovarian cancer at age 50 or
younger -2 or more close relatives with breast and/or pancreatic cancer -women of Ashkenazi Jewish descent at any age breast/ovarian
cancer.- Other cancer history – Thyroid, sarcoma, adrenal , endometrial,
pancreatic, brain cancer- Ovarian cancer- Male breast cancer.
![Page 11: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/11.jpg)
Patient NX
• NX 42 year old white female with no family history of breast cancer, now has 4 cm right breast cancer.
• Biopsy confirmed IDC,ER+, HER2/neu +• What’s next? – Surgery- ipsilateral or bilateral
mastectomy, chemo, hormonal therapy? Or more?
![Page 12: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/12.jpg)
Patient NX
• Should go I go for surgery first? Then chemo?• Blood for BRCA 1 and 2 mutation.
![Page 13: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/13.jpg)
Patient MB
• MB is a 53 year old white male with right sided breast cancer, stage I.
![Page 14: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/14.jpg)
BReastCAncer Genes
![Page 15: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/15.jpg)
BReast CAncer
• Women have about a 1 in 7 chance of getting breast cancer in their lifetime.
• Most cancer is sporadic, about 5-10% of cases are genetically linked
• Women inheriting mutation of BRCA gene have increased chance of disease
• Also can lead to ovarian cancer
![Page 16: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/16.jpg)
The Numbers
Frequency of BRCA Mutations in the U.S.
U.S. citizens 1 in 500
Ashkenazi Jews 1 in 40
Women with breast cancer under age 50 Approx. 1 in 13
Women with breast cancer under age 40 1 in 10
Ashkenazi Jews with breast cancer under age 50 Approx. 1 in 8
![Page 17: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/17.jpg)
BRCA Genes
• BRCA 1 and BRCA 2
• Roles they play
![Page 18: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/18.jpg)
Life is all about the right balance.
![Page 19: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/19.jpg)
What are they?
• BRCA 1 and BRCA 2– Known as breast and ovarian cancer susceptibility
genes– Tumor suppressor genes
• regulate the cycle of cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way
• inhibit the growth of cells that line the milk ducts in the breast
– Involved in many other functions including control of DNA replication and damage repair
![Page 20: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/20.jpg)
BRCA 1
• Cloned in 1994 (Miki et al)–Mapped to chromosome 17q21–5,592kb long–24 exons
![Page 21: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/21.jpg)
BRCA 2
• Cloned in 1995 (Wooster et al.)• Mapped to chromosome 13q12-13• 10,254 kb (3,418 aa)• 27 exons
![Page 22: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/22.jpg)
More Numbers
Type of Cancer
General Population That Will Develop Disease
People With BRCA1 Mutation Who Will Develop Disease
People With BRCA2 Mutation Who Will Develop Disease
Breast 12.5% 55 – 85% 33 – 86%
Ovarian 1.43% 28 – 44% 10 – 30%
Prostate 4 – 6% 12 – 18% 12 – 18%
Male breast cancer Less than 1% 6% 4 – 14%
Pancreatic 0.6% not applicable 6 – 7%
![Page 23: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/23.jpg)
Patient NX
• BRCA 1 mutation positive• Neo-adjuvant chemotherapy then bilateral
skin sparing mastectomy.• Hormonal therapy• Prophylactic bilateral salpingo-oopherectomy• Genetic counseling for family members.
![Page 24: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/24.jpg)
Patient MB
• BRCA 2 mutation positive• Chemotherapy• Contra-lateral mastectomy• PSA screening test.
![Page 25: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/25.jpg)
Topics
• Role of genetic/familial high risk assessment• Role of specific markers on breast tissue in
decision making of treatment.• For some patients, more is not better. - Role of genetic profiling of the tumor in decision making.
![Page 26: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/26.jpg)
How Do We Assess Risk in Breast Cancer Patients?
Classic Pathological Criteria
Age
Tumor Size
Lymph Node Status
ER/PRHER2
Tumor Grade
AdjuvantOnline!Computer-based model
![Page 27: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/27.jpg)
ER/PR/Her2-Neu
• Estrogen receptor• Progesterone receptor• Her2/Neu – Human epidermal growth factor
Receptor 2• ER/PR+ Her2/Neu –• ER/PR – Her2/Neu – (Triple negative)• ER/PR – Her2/Neu +• ER/PR+ Her2/Neu +
![Page 28: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/28.jpg)
Triple-Positive Breast Cancer
Triple-Negative Breast CancerH&E ER-Neg PR-Neg
HER2/neu-Neg
ER-Pos PR-Pos HER2/neu-PosH&E
![Page 29: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/29.jpg)
Treatment options Chemotherapy Endocrine therapy – Tamoxifen or Aromatase
inhibitor - Anastrozole (Arimidex) , Letrozole (Femara) , Exemestane (Aromasin)
Trastuzumab (Herceptin)
![Page 30: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/30.jpg)
HerceptinTM(trastuzumab)
![Page 31: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/31.jpg)
Triple negative breast cancerHormone Receptor - /HER2 -
• Chemotherapy for tumor more than 0.5 cm.• Nodal involvement.
![Page 32: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/32.jpg)
Hormone Receptor Positive,HER2 Positive Breast Cancer
• 0.5 cm or less tumor size – Adjuvant endocrine therapy
• 0.6 to 1 cm – Adjuvant endocrine +/- chemo with trastuzumab.
• > 1 cm tumor size and/or lymph node involvement – adjuvant endocrine therapy, chemotherapy with trastuzumab.
![Page 33: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/33.jpg)
Hormone Receptor Negative,HER2 Positive Breast Cancer
• 0.5 cm or less tumor size – No chemo.• 0.6 to 1 cm – Consider chemo with trastuzumab.• > 1 cm tumor size and/or lymph node involvement –
chemotherapy with trastuzumab.• HORMONAL THERAPY NOT USEFUL.
![Page 34: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/34.jpg)
Hormone Receptor Positive,HER2 Positive Breast Cancer
• 0.5 cm or less tumor size – Adjuvant endocrine therapy
• 0.6 to 1 cm – Adjuvant endocrine +/- chemo with trastuzumab.
• > 1 cm tumor size and/or lymph node involvement – adjuvant endocrine therapy, chemotherapy with trastuzumab.
![Page 35: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/35.jpg)
Hormone Receptor Positive HER2 Negative Breast Cancer -
Tumor size
• Tumor size < 0.5 Cm and No LN involvement – Adjuvant endocrine therapy. No chemotherapy
• T > 0.5 Cm and No LN involvement - adjuvant endocrine therapy +/- ?? Chemo.
![Page 36: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/36.jpg)
Hormone Receptor Positive HER2 Negative Breast Cancer
• Nodal involvement > 2mm focus – adjuvant endocrine therapy + chemotherapy
• 1 to 3 Lymph nodes or >3 nodes involved – does every one need chemo?
![Page 37: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/37.jpg)
Topics
• Role of genetic/familial high risk assessment• Role of specific markers on breast tissue in
decision making of treatment.• For some patients, more(=chemotherapy) is
not better. - Role of genetic profiling of the tumor in decision making.
![Page 38: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/38.jpg)
How Do We Assess Risk in Breast Cancer Patients?
Classic Pathological Criteria
Genetic Profiling of Tumor
New tools in the Genomic Era…
Age
Tumor Size
Lymph Node Status
ER/PRHER2
Tumor Grade
AdjuvantOnline!Computer-based model
![Page 39: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/39.jpg)
Adjuvant Treatment for Early Stage Breast Cancer Today
![Page 40: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/40.jpg)
Hormonal Therapy
If 100 women with ER+, N- disease are treated with hormonal therapy how many will recur within 10 years?
Based on the Landmark NSABP B-14 Study using Tamoxifen
85
15 Recurrence
Disease free
Fisher et al. N Engl J Med 1989;320(8):479-84
![Page 41: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/41.jpg)
Chemotherapy and Hormonal Therapy
If all 100 women with ER+, N- disease are treated with chemotherapy and hormonal therapy, how many will benefit from the addition of chemotherapy?
Based on the Landmark NSABP B-20 Study using Tamoxifen + Chemotherapy
4
85
11Benefited fromChemotherapy
Relapsed despiteChemotherapy
Disease freeregardless ofChemotherapy
Fisher et al. J Natl Cancer Inst 1997;89:1673-82
![Page 42: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/42.jpg)
Copyright © American Society of Clinical Oncology
Outcomes of Adjuvant Chemotherapy in Breast Cancer
Walgren et al. JCO 2005;23:7342-7349
![Page 43: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/43.jpg)
How Do We Assess Risk in Breast Cancer Patients?
Classic Pathological Criteria
Genetic Profiling of Tumor
New tools in the Genomic Era…
Age
Tumor Size
Lymph Node Status
ER/PRHER2
Tumor Grade
AdjuvantOnline!Computer-based model
![Page 44: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/44.jpg)
Patient A
![Page 45: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/45.jpg)
Patient B
![Page 46: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/46.jpg)
Patient C
![Page 47: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/47.jpg)
With Genomic Tools We Can Now Analyze Cancer at the Molecular Level
1. Patient’s tumor
4. Oncotype DX® Report
3. Analyze expression of tumor’s genes
2. Oncotype DX® Assay
5. Shared Decision Making
![Page 48: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/48.jpg)
Oncotype DX®: A Genomic Assay
![Page 49: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/49.jpg)
Oncotype DX® 21-Gene Recurrence Score® (RS) Assay
PROLIFERATIONKi-67STK15SurvivinCyclin B1MYBL2
ESTROGENERPRBcl2SCUBE2
INVASIONStromelysin 3Cathepsin L2
HER2GRB7HER2
BAG1GSTM1
REFERENCEBeta-actinGAPDHRPLPOGUSTFRC
CD68
16 Cancer and 5 Reference Genes From 3 Studies
Paik et al. N Engl J Med. 2004;351: 2817-2826
![Page 50: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/50.jpg)
Oncotype DX® 21-Gene Recurrence Score® (RS) Assay
Calculation of the Recurrence Score Result
Category RS (0-100)Low risk RS <18
Int risk RS ≥18 and <31
High risk RS ≥31
Paik et al. N Engl J Med. 2004;351: 2817-2826
RS =Coefficient x Expression Level+ 0.47 x HER2 Group Score - 0.34 x ER Group Score + 1.04 x Proliferation Group Score+ 0.10 x Invasion Group Score + 0.05 x CD68- 0.08 x GSTM1- 0.07 x BAG1
![Page 51: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/51.jpg)
The Oncotype DX® Assay mostly used for N-, ER+ Breast Cancer Patients
Invasive Breast Cancer
Stage I Stage II Stage III Stage IV
ER- ER+ N- N+
ER- ER+
![Page 52: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/52.jpg)
Patient A
![Page 53: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/53.jpg)
Patient A
• Patient was identified as low risk by Oncotype DX® with a Recurrence Score ® result of 4
• Patient received hormonal therapy since she was in a group in which chemotherapy does not provide benefit
![Page 54: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/54.jpg)
Patient B
![Page 55: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/55.jpg)
• Patient was identified as high risk by Oncotype DX® with a Recurrence Score® result of 34
• The Recurrence Score helped convince the patient on the likely benefits of taking chemotherapy given the biology of her disease
• Patient received chemotherapy and hormonal therapy
Patient B
![Page 56: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/56.jpg)
Patient C
![Page 57: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/57.jpg)
• Patient was identified as intermediate risk by Oncotype DX® with a Recurrence Score® result of 25
• Is there benefit from chemotherapy for this patient? The TAILORx trial evaluates the utility of chemotherapy in the mid-range risk group
Patient C
![Page 58: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/58.jpg)
Copyright © American Society of Clinical Oncology
Outcomes of Adjuvant Chemotherapy in Breast Cancer
Walgren et al. JCO 2005;23:7342-7349
![Page 59: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/59.jpg)
TamoxifenTamoxifen
ChemotherapyChemotherapyAnth, Taxane, Anth, Taxane,
PlatimunPlatimun
Women with Women with HR+ breast HR+ breast
CancerCancerAromatase Aromatase
InhibitorInhibitor
Biologic agentsBiologic agentsHer2, EGFR, VEGF, ParpHer2, EGFR, VEGF, Parp
The Promise of Personalized Medicine in Breast Cancer
![Page 60: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/60.jpg)
The Molecular Portrait Hypothesis
You can recognize theMona Lisa by her smile
and her nose and her eyes and even her hands – if you are really good,but not the sky or the trees
![Page 61: Personalized Breast Cancer Care](https://reader036.vdocuments.site/reader036/viewer/2022070420/56815e25550346895dcc7f3e/html5/thumbnails/61.jpg)
Thank you.
Questions?